| Target Price | $30.60 |
| Price | $32.34 |
| Deviation |
5.38%
register free of charge
|
| Number of Estimates | 15 |
|
15 Analysts have issued a price target Oscar Health 2027 .
The average Oscar Health target price is $30.60.
This is
5.38%
register free of charge
$40.95
26.62%
register free of charge
$8.08
75.02%
register free of charge
|
|
| A rating was issued by 19 analysts: 9 Analysts recommend Oscar Health to buy, 9 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Oscar Health stock has an average upside potential 2027 of
5.38%
register free of charge
|
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion $ | 11.70 | 19.13 |
| 27.50% | 63.48% | |
| EBITDA Margin | -3.14% | 4.24% |
| 422.35% | 235.02% | |
| Net Margin | -3.79% | 2.98% |
| 1,466.76% | 178.69% |
14 Analysts have issued a sales forecast Oscar Health 2026 . The average Oscar Health sales estimate is
This results in the following potential growth metrics:
15 Analysts have issued an Oscar Health EBITDA forecast 2026. The average Oscar Health EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
15 Oscar Health Analysts have issued a net profit forecast 2026. The average Oscar Health net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.69 | 1.84 |
| 1,790.00% | 208.88% | |
| P/E | 17.53 | |
| EV/Sales | 0.32 |
15 Analysts have issued a Oscar Health forecast for earnings per share. The average Oscar Health EPS is
This results in the following potential growth metrics and future valuations:
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Raymond James |
Locked
➜
Locked
|
Locked | Sep 18 2026 |
| Barclays |
Locked
➜
Locked
|
Locked | Sep 17 2026 |
| B of A Securities |
Locked
➜
Locked
|
Locked | Sep 17 2026 |
| Baird |
Locked
➜
Locked
|
Locked | Sep 17 2026 |
| Stephens & Co. |
Locked
➜
Locked
|
Locked | Sep 17 2026 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Aug 13 2026 |
| Barclays |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Raymond James:
Locked
➜
Locked
|
Sep 18 2026 |
|
Locked
Barclays:
Locked
➜
Locked
|
Sep 17 2026 |
|
Locked
B of A Securities:
Locked
➜
Locked
|
Sep 17 2026 |
|
Locked
Baird:
Locked
➜
Locked
|
Sep 17 2026 |
|
Locked
Stephens & Co.:
Locked
➜
Locked
|
Sep 17 2026 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Aug 13 2026 |
|
Locked
Barclays:
Locked
➜
Locked
|
Aug 07 2026 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


